{"analyses":[{"ciLowerLimit":"-0.7","ciPctValue":"95","ciUpperLimit":"-0.1","groupDescription":"Assessed using an analysis of variance (ANOVA) model, with retreatment group, baseline DAS28-ESR score, baseline RF status, and ≥20% improvement in both SJC and TJC at Week 24 from baseline (yes/no) as explanatory terms in the model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Mean Difference (Final Values)","paramValue":"-0.4","statisticalComment":"Adjusted mean for Arm A (Rituxan) is -1.9 and adjusted mean for Arm B (Placebo) is -1.5.","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.55","value":"-2.1"},{"groupId":"OG001","spread":"1.69","value":"-1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Retreatment"}],"paramType":"MEAN","populationDescription":"Participants from the Intent-to-treat population, that includes all participants randomized to Retreatment, with data available for analyses.","reportingStatus":"POSTED","timeFrame":"48 weeks","title":"Change From Baseline in the Disease Activity Score Using 28 Joint Counts (DAS28-ESR) at Week 48","type":"SECONDARY","unitOfMeasure":"Units on a scale"}